report
also
describ
absenc
efficaci
serotherapi
given
later
diseas
cours
sarscoronaviru
day
day
avail
evid
suggest
viral
replic
activ
viral
load
peak
earlier
period
could
affect
therapeut
time
window
antivir
agent
eg
day
neuraminidas
inhibitor
highest
benefit
given
day
sever
infect
observ
futil
nonspecif
ivig
suggest
predomin
role
serotherapi
could
neutralis
inhibit
invad
viru
although
mechan
immunomodul
might
coexist
viral
load
reduct
shown
beigel
colleagu
main
analysi
subanalysi
data
accord
viru
subtyp
respect
viru
neutralis
antibodi
titr
futur
data
low
haemagglutin
inhibit
titr
versu
high
haemagglutin
inhibit
titr
antibodi
concentr
plasma
trial
might
provid
addit
insight
help
defin
actual
effect
titr
dose
bodyweight
efficaci
establish
would
import
defin
patient
group
would
benefit
adjunct
serotherapi
addit
neuraminidas
inhibitor
current
consid
standard
care
sever
prognost
index
base
present
clinic
laboratori
paramet
eg
pao
fio
ratio
acut
physiolog
chronic
health
evalu
apach
ii
metabolom
propos
might
assist
risk
stratif
magnitud
improv
outcom
neuraminidas
inhibitor
treatment
alon
risktobenefit
ratio
need
address
sever
potenti
safeti
concern
